These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

927 related items for PubMed ID: 30772960

  • 21. Relationships between serum PSA levels, Gleason scores and results of 68Ga-PSMAPET/CT in patients with recurrent prostate cancer.
    Sanli Y, Kuyumcu S, Sanli O, Buyukkaya F, İribaş A, Alcin G, Darendeliler E, Ozluk Y, Yildiz SO, Turkmen C.
    Ann Nucl Med; 2017 Nov; 31(9):709-717. PubMed ID: 28900854
    [Abstract] [Full Text] [Related]

  • 22. Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer.
    Calais J, Kishan AU, Cao M, Fendler WP, Eiber M, Herrmann K, Ceci F, Reiter RE, Rettig MB, Hegde JV, Shaverdian N, King CR, Steinberg ML, Czernin J, Nickols NG.
    J Nucl Med; 2018 Nov; 59(11):1714-1721. PubMed ID: 29653978
    [Abstract] [Full Text] [Related]

  • 23. The role of histopathological and biochemical parameters for predicting metastatic disease on 68 Ga-PSMA-11 PET in prostate cancer.
    Aydos U, Çetin S, Akdemir ÜÖ, Budak FÇ, Ateş SG, Koparal MY, Gönül İI, Gülbahar Ö, Sözen S, Atay LÖ.
    Prostate; 2021 Dec; 81(16):1337-1348. PubMed ID: 34516677
    [Abstract] [Full Text] [Related]

  • 24. 68Ga-PSMA PET/CT for Primary Lymph Node and Distant Metastasis NM Staging of High-Risk Prostate Cancer.
    Klingenberg S, Jochumsen MR, Ulhøi BP, Fredsøe J, Sørensen KD, Borre M, Bouchelouche K.
    J Nucl Med; 2021 Feb; 62(2):214-220. PubMed ID: 32444374
    [Abstract] [Full Text] [Related]

  • 25. Correlations between whole body volumetric parameters of 68Ga-PSMA PET/CT and biochemical-histopathological parameters in castration-naive and resistant prostate cancer patients.
    Yildirim ÖA, Gündoğan C, Can C, Poyraz K, Erdur E, Kömek H.
    Ann Nucl Med; 2021 May; 35(5):540-548. PubMed ID: 33586097
    [Abstract] [Full Text] [Related]

  • 26. Findings in 1,123 Men with Preoperative 68Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography and Multiparametric Magnetic Resonance Imaging Compared to Totally Embedded Radical Prostatectomy Histopathology: Implications for the Diagnosis and Management of Prostate Cancer.
    Raveenthiran S, Yaxley WJ, Franklin T, Coughlin G, Roberts M, Gianduzzo T, Kua B, Samaratunga H, Delahunt B, Egevad L, Wong D, McEwan L, Brown N, Parkinson R, Esler R, Yaxley JW.
    J Urol; 2022 Mar; 207(3):573-580. PubMed ID: 34694140
    [Abstract] [Full Text] [Related]

  • 27. Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer.
    Park SY, Zacharias C, Harrison C, Fan RE, Kunder C, Hatami N, Giesel F, Ghanouni P, Daniel B, Loening AM, Sonn GA, Iagaru A.
    Radiology; 2018 Aug; 288(2):495-505. PubMed ID: 29786490
    [Abstract] [Full Text] [Related]

  • 28. Extent of disease in recurrent prostate cancer determined by [(68)Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score.
    Verburg FA, Pfister D, Heidenreich A, Vogg A, Drude NI, Vöö S, Mottaghy FM, Behrendt FF.
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):397-403. PubMed ID: 26563121
    [Abstract] [Full Text] [Related]

  • 29. Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study.
    Lenis AT, Pooli A, Lec PM, Sadun TY, Johnson DC, Lebacle C, Fendler WP, Eiber M, Czernin J, Reiter RE, Calais J.
    Eur Urol Oncol; 2022 Oct; 5(5):544-552. PubMed ID: 32958451
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Establishment and prospective validation of an SUVmax cutoff value to discriminate clinically significant prostate cancer from benign prostate diseases in patients with suspected prostate cancer by 68Ga-PSMA PET/CT: a real-world study.
    Jiao J, Kang F, Zhang J, Quan Z, Wen W, Zhao X, Ma S, Wu P, Yang F, Guo W, Yang X, Yuan J, Shi Y, Wang J, Qin W.
    Theranostics; 2021 Oct; 11(17):8396-8411. PubMed ID: 34373749
    [Abstract] [Full Text] [Related]

  • 33. Comparison of 68Ga-PSMA-617 PET/CT and 68Ga-RM2 PET/CT in Patients with Localized Prostate Cancer Who Are Candidates for Radical Prostatectomy: A Prospective, Single-Arm, Single-Center, Phase II Study.
    Schollhammer R, Robert G, Asselineau J, Yacoub M, Vimont D, Balamoutoff N, Bladou F, Bénard A, Hindié E, Gallerande HC, Morgat C.
    J Nucl Med; 2023 Mar; 64(3):379-385. PubMed ID: 36215569
    [Abstract] [Full Text] [Related]

  • 34. Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
    Schmidt-Hegemann NS, Fendler WP, Buchner A, Stief C, Rogowski P, Niyazi M, Eze C, Li M, Bartenstein P, Belka C, Ganswindt U.
    Radiat Oncol; 2017 Nov 10; 12(1):176. PubMed ID: 29126446
    [Abstract] [Full Text] [Related]

  • 35. Bone scintigraphy as a gatekeeper for the detection of bone metastases in patients with prostate cancer: comparison with Ga-68 PSMA PET/CT.
    Caglar M, Tuncel M, Yildiz E, Karabulut E.
    Ann Nucl Med; 2020 Dec 10; 34(12):932-941. PubMed ID: 32975741
    [Abstract] [Full Text] [Related]

  • 36. Utility of Ga68 prostate-specific membrane antigen positron-emission tomography for pre-operative staging of high-risk prostate cancer in a prospective cohort.
    Tarr GP, Kashyap P, Dixit DD, Willams AK, Koya MP, Lim R.
    J Med Imaging Radiat Oncol; 2020 Feb 10; 64(1):78-86. PubMed ID: 31885207
    [Abstract] [Full Text] [Related]

  • 37. The Relationship between D'Amico and ISUP Risk Classifications and 68Ga-PSMA PET/CT SUVmax Values in Newly Diagnosed Prostate Cancers.
    Ulas Babacan O, Hasbek Z, Seker K.
    Curr Oncol; 2024 Sep 08; 31(9):5307-5317. PubMed ID: 39330019
    [Abstract] [Full Text] [Related]

  • 38. 68Ga-PSMA Positron Emission Tomography/Computed Tomography Provides Accurate Staging of Lymph Node Regions Prior to Lymph Node Dissection in Patients with Prostate Cancer.
    Herlemann A, Wenter V, Kretschmer A, Thierfelder KM, Bartenstein P, Faber C, Gildehaus FJ, Stief CG, Gratzke C, Fendler WP.
    Eur Urol; 2016 Oct 08; 70(4):553-557. PubMed ID: 26810345
    [Abstract] [Full Text] [Related]

  • 39. Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI, (68)Ga-PSMA PET/CT, PSA, and PSA-density comparison study.
    Akkaya H, Dilek O, Özdemir S, Taş ZA, Öztürk İS, Gülek B.
    Diagn Interv Radiol; 2023 Sep 05; 29(5):647-655. PubMed ID: 37395389
    [Abstract] [Full Text] [Related]

  • 40. Intra-individual comparison of prostate-specific membrane antigen positron emission tomography/computed tomography versus bone scan in detecting skeletal metastasis at prostate cancer diagnosis.
    Shanmugasundaram R, Saad J, Heyworth A, Wong V, Pelecanos A, Arianayagam M, Canagasingham B, Ferguson R, Goolam AS, Khadra M, Kam J, Ko R, McCombie S, Varol C, Winter M, Mansberg R, Nguyen D, Bui C, Loh H, Le K, Roberts MJ.
    BJU Int; 2024 Feb 05; 133 Suppl 3():25-32. PubMed ID: 37943964
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 47.